Urteste (WSE:URT) - Share price, News & Analysis

URT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

URT Stock Overview

Urteste S.A. engages in the research and development of diagnostic tests for cancers.

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (PLN94M)

Urteste Competitors

Pure Biologics Spólka Akcyjna

WSE:PUR

zł66.5m

Poltreg

WSE:PTG

zł158.1m

Genomed Spólka Akcyjna

WSE:GEN

zł51.5m

Genomtec

WSE:GMT

zł48.7m

Price History & Performance

Summary of all time highs, changes and price drops for Urteste
Historical stock prices
Current Share Price	zł82.80
52 Week High	zł110.00
52 Week Low	zł77.00
Beta	0
1 Month Change	-2.59%
3 Month Change	-7.80%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-16.19%

Shareholder Returns

	URT	PL Biotechs	PL Market
7D	4.8%	-4.3%	-7.9%
1Y	n/a	-43.4%	-35.7%

Return vs Industry: Insufficient data to determine how URT performed against the Polish Biotechs industry.

Return vs Market: Insufficient data to determine how URT performed against the Polish Market.

Price Volatility

Is URT's price volatile compared to industry and market?
URT volatility
URT Average Weekly Movement	3.5%
Biotechs Industry Average Movement	10.5%
Market Average Movement	6.1%
10% most volatile stocks in PL Market	11.7%
10% least volatile stocks in PL Market	3.8%

Stable Share Price: URT is less volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: URT's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2021	n/a	Grzegorz Stefanski	https://www.urteste.com

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for breast, pancreatic, prostate, kidney, colorectal, liver, stomach, lung, throat, bile duct, ovary, uterus, blood, and nervous system cancers. The company was incorporated in 2021 and is based in Gdansk, Poland.

Urteste Fundamentals Summary

How do Urteste's earnings and revenue compare to its market cap?
URT fundamental statistics
Market Cap	zł94.42m
Earnings (TTM)	zł0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is URT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
URT income statement (TTM)
Revenue	zł0
Cost of Revenue	zł0
Gross Profit	zł0
Other Expenses	zł0
Earnings	zł0

Last Reported Earnings

n/a

Next Earnings Date

Nov 10, 2022

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did URT perform over the long term?

See historical performance and comparison

We’ve recently updated our valuation analysis.

Valuation

Is URT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for URT?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for URT. This is calculated by dividing URT's market cap by their current preferred multiple.
What is URT's n/a Ratio?
n/a Ratio	0x
n/a	n/a
Market Cap	zł94.42m

URT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does URT's PB Ratio compare to its peers?

URT PB Ratio vs Peers

The above table shows the PB ratio for URT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	PB	Estimated Growth	Market Cap
Peer Average	5.3x
PUR Pure Biologics Spólka Akcyjna	2.3x	n/a	zł66.5m
PTG Poltreg	1.5x	n/a	zł158.1m
GEN Genomed Spólka Akcyjna	6.1x	n/a	zł51.5m
GMT Genomtec	11.3x	n/a	zł48.7m
URT Urteste	n/a	n/a	zł94.4m

Price-To-Book vs Peers: Insufficient data to calculate URT's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Earnings Ratio vs Industry

How does URT's PE Ratio compare vs other companies in the European Biotechs Industry?

Price-To-Book vs Industry: Insufficient data to calculate URT's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is URT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

URT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate URT's Price-To-Book Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of URT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate URT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate URT's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Take a look at our analysis of URT's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Urteste regulatory filings.

Future Growth

How is Urteste forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

40.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Urteste has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

Take a look at our analysis of URT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
Urteste competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Urteste performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

15.9%

Historical Pharmaceuticals & Biotech annual earnings growth

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Urteste has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Discover strong past performing companies

When a company lacks a financial track record, its management’s track record becomes important. Corporate governance also plays an important role in a young business as board members are seen as highly-experienced leaders to help steer the company into the future. Take a look at Urteste's management and board experience and expertise to assess their ability to deliver on their strategic promises.

Financial Health

How is Urteste's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

In this section we usually analyse Urteste's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Urteste has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.

Discover healthy companies

Take a look at our analysis of URT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Urteste's cash and debt levels may be found in its annual reports archived here.
Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Urteste's financial data was last updated here.

Dividend

What is Urteste current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage

Dividend Yield vs Market

Urteste Dividend Yield vs Market

How does Urteste dividend yield compare to the market?
Segment	Dividend Yield
Company (Urteste)	n/a
Market Bottom 25% (PL)	3.1%
Market Top 25% (PL)	9.6%
Industry Average (Biotechs)	2.2%
Analyst forecast in 3 Years (Urteste)	n/a

Notable Dividend: Unable to evaluate URT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate URT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if URT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if URT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as URT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average board tenure

CEO

Grzegorz Stefanski

no data

Tenure

Mr. Grzegorz Stefanski is President of the Management Board at Urteste S.A. He had been Member of the Management at BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. since September 29, 2017. He has exper...

Board Members

Experienced Board: URT's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of URT?
Owner Type	Number of Shares	Ownership Percentage
Institutions	40,518	3.6%
General Public	73,668	6.5%
Private Companies	204,918	18.0%
Individual Insiders	821,176	72.0%

Dilution of Shares: URT only recently listed within the past 12 months.

Top Shareholders

Top 7 shareholders own 93.54% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
21.21%	Adam Lesner	241,808	PLN20.0m	0%	no data
18.33%	Natalia Gruba	209,018	PLN17.3m	0%	no data
17.97%	Twiti Investments Limited	204,918	PLN17.0m	0%	no data
16.31%	Grzegorz Stefanski	185,928	PLN15.4m	0.03%	no data
16.17%	Tomasz Kostuch	184,422	PLN15.3m	0%	no data
3.53%	Aviva Investors Poland Towarzystwo Funduszy Inwestycyjnych S.A.	40,268	PLN3.3m	0%	0.28%
0.022%	Lartiq Towarzystwo Funduszy Inwestycyjnych S.A.	250	PLN20.7k	0%	0.02%

Data	Last Updated (UTC time)
Company Analysis	2022/09/29 00:00
End of Day Share Price	2022/09/29 00:00
Earnings	N/A
Annual Earnings	N/A